NVO - Eli Lilly oral weight-loss candidate orfoglipron is potential winner: SA Summit
2024-06-18 13:49:28 ET
More on Eli Lilly
- Eli Lilly And Alzheimer's Disease: The Paucity Of Progress
- Eli Lilly: The Road To Approval Of Donanemab Is Open
- Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference
- Eli Lilly’s oral weight-loss drug is potential winner, analyst says
- Ozempic drives more demand for smaller clothes, WSJ reports